In summary, this study supports that genistein-mediated TFEB activation corrects pathological phenotypes in NPC models and substantiates the need for further studies of this isoflavonoid as a potential therapeutic agent to treat NPCD and other LSDs with neurological compromise. This evidence concerns the gene TFEB and nasopharyngeal carcinoma.